Healthcare Equipment and Supplies
Company Overview of Nobel Biocare Holding AG
Nobel Biocare Holding AG operates in the field of implant-based dental restorations worldwide. It offers dental implants for various indications, bone types, and surgical protocols under the NobelActive, Brånemark System, and NobelReplace brands; high-precision individualized prosthetics and CAD/CAM systems for every indication, from a single tooth to edentulous jaws, on natural teeth and implants under the NobelProcera brand; and machined and TiUnite implants. The company also provides a range of individualized CAD/CAM abutments and a portfolio of prefabricated temporary and final abutments; biomaterials for soft tissue and bone regeneration under the creos brand; and removable and fixed im...
Balz Zimmermann-Strasse 7
Founded in 1981
Key Executives for Nobel Biocare Holding AG
Chief Executive Officer
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2013.
Nobel Biocare Holding AG Key Developments
Danaher Corp., Nobel Biocare Holding AG - M&A Call
Sep 15 14
To enter into definitive transaction agreement with Nobel Biocare Holding AG
Nobel Biocare Holding AG Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-03-2014
Sep 5 14
Nobel Biocare Holding AG Presents at Goldman Sachs 11th Annual European Medtech And Healthcare Services Conference, Sep-03-2014 . Venue: London, United Kingdom.
Nobel Biocare Holding AG Reports Earnings Results for the Six Months of 2014; Revised Earnings Guidance for 2014
Aug 21 14
Nobel Biocare Holding AG reported earnings results for the six months of 2014. For the first six months, the company's revenue was EUR 283 million, up 2.5% from last year at constant exchange rates. In its reporting currency, sales were down 2.2% due to ongoing significant adverse currency impact. Speaking of currencies, the company experienced in the second quarter a continued adverse impact comparable to the one in the first quarter throughout the whole P&L. This also led to a less favorable net financial result than in the same period a year ago. The reduction of the operating expense led to a material expansion of the operating profit and the respective margin on a like-for-like basis. Operating profit was up 26% compared with last year and excluding the nonrecurring cost in 2013. EBIT margin was at 15%. Constant exchange rate, the margin would have been at 15.8%, up around 300 basis points from a year ago. Net profit was EUR 42 million, which was up 25% at constant exchange rates over last year, reflecting a net profit margin of now around 10%. Cash flow from operating activities was solid in the first half of the year, but around EUR 7 million below last year. The reason for this is higher cash outflows from accrued expenses for bonuses and taxes compared to a year ago.
The company maintained its outlook of 3% to 4% revenue growth for the year. The company will need to accelerate revenue growth in the second half. The company is upping the EBIT margin outlook to 150 to 200 for the year against the previous outlook. As a result of the good progress expanding its EBIT margin, the company increased its operating margin guidance for the full year 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 15, 2014
Most Searched Private Companies
Sponsored Financial Commentaries